Welcome to our dedicated page for Terns Pharmaceuticals news (Ticker: TERN), a resource for investors and traders seeking the latest updates and insights on Terns Pharmaceuticals stock.
Terns Pharmaceuticals was a clinical-stage oncology company whose TERN news centered on TERN-701, an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor for chronic myeloid leukemia. Company updates covered clinical and regulatory disclosures for TERN-701, licensing arrangements tied to the program, operating and financial results, equity compensation actions, and shareholder or capital-structure matters.
In May 2026, Merck completed its acquisition of Terns, and Terns became a wholly owned subsidiary of Merck. The company’s common stock was removed from Nasdaq trading, making TERN a historical public-company ticker tied to the oncology program and the completed corporate-status change.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Terns Pharmaceuticals, Inc. announced significant leadership changes and reported financial results for Q4 and the full year ending December 31, 2022. The company appointed Emil Kuriakose as chief medical officer for oncology, enhancing its R&D capabilities. As of December 31, 2022, Terns held $283 million in cash, sufficient to fund operations into 2026. For Q4, the net loss was $15.8 million, slightly up from $14.2 million year-over-year. R&D expenses rose to $10.7 million, while G&A expenses increased to $6.2 million. License revenue remained stagnant at $0, indicating a focus on clinical development over commercial activities.
Terns Pharmaceuticals has appointed Emil Kuriakose, M.D., as Chief Medical Officer for oncology, effective May 1, 2023. Dr. Kuriakose has over a decade of experience in clinical development, notably in oncology, previously serving as Chief Medical Officer at Calithera Biosciences and holding key roles at Novartis. His expertise is expected to advance Terns' clinical program for TERN-701, targeting chronic myeloid leukemia (CML), addressing significant unmet needs in treatment options. Kerry Russell, M.D., will transition to Chief Medical Officer for Terns’ metabolic programs focusing on NASH and obesity.
Terns Pharmaceuticals (Nasdaq: TERN) has completed enrollment in the Phase 2a DUET clinical trial for TERN-501, a THR-β agonist for treating NASH, with top-line results anticipated in Q3 2023. The company plans to initiate a U.S. clinical trial for TERN-701, an allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML), in the second half of 2023. Additionally, Terns is preparing for a Phase 1 clinical trial for TERN-601, a GLP-1 receptor agonist for obesity, also set for H2 2023. Terns' cash reserves are expected to last into 2026, supporting its ongoing research and development initiatives.